On October 6, 2025, MiMedx Group, Inc. announced the launch of EPIXPRESS®, a new addition to its Advanced Wound Care portfolio. Chief Executive Officer Joseph H. Capper highlighted that the product builds on the success of EPIEFFECT by adding fenestrations to allow fluid movement through the tissue, and that it is an organically developed, lyophilized placental allograft processed with the company’s PURION® technology.
EPIXPRESS is a tri‑layer, lyophilized product that includes the amnion, intermediate, and chorion layers and contains over 300 regulatory proteins. The fenestrated design provides a barrier while permitting fluid movement, making it suitable for a range of wound types, including diabetic foot ulcers, venous leg ulcers, and deep or tunneling wounds that require secure graft placement with sutures.
The launch expands MiMedx’s product line to address both acute and chronic, hard‑to‑heal wounds, broadening the company’s market reach. By offering a fenestrated allograft, MiMedx can target clinicians who need enhanced fluid management in wound care, potentially increasing adoption across its existing customer base and opening new revenue streams.
EPIXPRESS is listed on the Medicare Part B Average Sales Price File, positioning it for reimbursement under current Medicare rules. The product’s addition to MiMedx’s portfolio reinforces the company’s strategy of leveraging its proprietary PURION process to deliver evidence‑based, high‑performance wound care solutions, supporting continued growth in the advanced wound care market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.